Clinical trials: Endometrial Bleeding
Heavy Menstrual Bleeding
Impact of Incomplete Endometrial Ablation
The aim of the proposed protocol is to study the impact of incomplete endometrial ablation on the PBAC score, reintervention, satisfaction, controlled bleeding and dysmenorrhea at 24 months after Novasure endometrial ablation, in…
- Trial name
- NCT06122363
- Testing
- hysteroscopy
- Where
- Netherlands
- Volunteers
- 121 people
- Sponsor
- Maxima Medical Center
Endometrial Polyp, Endometrial Cancer
Endometrial Polyps: Pathophysiology and Clinical Consequences
The aim of these studies is to study the natural history, the symptoms of, as well as the effect of hysteroscopic resection of endometrial polyps.
- Trial name
- NCT00247923
- Testing
- Hysteroscopic resection of endometrial polyps. (TCRP)
- Where
- Norway
- Volunteers
- 1,186 people, healthy volunteers welcome
- Sponsor
- Ullevaal University Hospital
Postmenopausal Bleeding
Evaluation of DNA Methylation Markers for Endometrial Cancer Risk-stratification Using Patient-collected Urine and Vaginal Samples and Clinician-collected Cervical Samples From Women With Postmenopausal Bleeding
The goal of this observational study is to investigate the clinical utility of DNA-methylation testing in urine and vaginal samples collected by patients and cervical samples collected by clinicians, to determine the risk of…
- Trial name
- NCT07400835
- Testing
- DNA-methylation testing in patient-collected urine and vaginal samples and clinician-collected cervical samples
- Where
- 3 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- University of Aarhus
Uterine Bleeding, Treatment Failures
Clinical Predictive Factors of Success of Hysteroscopic Endometrial Ablation/Resection
To determine the predictive factors of endometrial ablation failure in the management of uterine bleeding.
- Conditions
- Uterine Bleeding, Treatment Failures, Prognostic Factors
- Trial name
- NCT05483348
- Testing
- Endometrial Ablation, Repeated gynecological procedure
- Where
- Jordan
- Volunteers
- 95 people
- Sponsor
- Naser Al-Husban
Abnormal Uterine Bleeding
DAta MIning to Evaluate Novasure Treatment
Abnormal Uterine Bleeding (AUB) is a common health problem that affects approximately 30% of women of reproductive age and can have several underlying causes.
- Trial name
- DAMIEN (NCT05299801)
- Where
- Netherlands
- Volunteers
- 1,038 people
- Sponsor
- Maxima Medical Center
Postmenopausal Bleeding, Endometrial Cancer
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
Postmenopausal bleeding (PMB) is the occurrence of vaginal bleeding 12 months following a woman's last menstrual cycle. PMB represents one of the most common reasons for referral to gynaecology services.
- Conditions
- Postmenopausal Bleeding, Endometrial Cancer, Endometrial Hyperplasia
- Trial name
- NCT05378152
- Testing
- Pipelle biopsy catheter
- Where
- Ireland
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Postmenopausal Women, Intrauterine Diseases
Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies
The goal of this randomized controlled trial is to evaluate the effectiveness of different cervical preparation strategies before office hysteroscopy in postmenopausal women undergoing evaluation for intrauterine pathology.
- Conditions
- Postmenopausal Women, Intrauterine Diseases, Endometrial Pathology, Postmenopausal Bleeding
- Trial name
- NCT07697781
- Testing
- No Cervical Preparation, Misoprostol ( Cytotec) 200 microgram a tablet, Vaginal Estrogen (7-Day Regimen)
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Faculty of Medicine of Tunis
Dysfunctional Uterine Bleeding
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg
The comparator drug (Zoladex 3.6 mg) is approved for use as a thinning agent for the endometrium prior to endometrial ablation. The dosing recommendation is one or two depots with each depot given four weeks apart.
- Trial name
- NCT04428684
- Testing
- Pepti 3.6 mg
- Where
- 5 sites in Ukraine
- Volunteers
- 80 people
- Sponsor
- Peptigroupe Inc.